社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
卡朋特科技(CRS)
盘后
395.99
4.48
+1.14%
19:58 EDT
391.51
-12.81
-3.17%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
今朝新闻
·
04-01 20:41
税务总局:已有7000万纳税人申请退还个税
4月1日,国家税务总局政策法规司司长戴诗友在税务总局新闻发布会上表示,今年个税汇算已进行了一个月,超过7000万纳税人已依法申请退税,还有超过500万纳税人自行依法申报补税,整体运行平稳有序。 戴诗友表示,个税汇算办理时间将持续至6月30日,请大家合理安排时间、错峰申报,尽量避开6月底高峰期。可以退税的纳税人抓紧领取退税“红包”;需要补税的纳税人,请在规定时间内申报并补缴税款,避免逾期产生滞纳金,造成不必要的损失。 他提醒,按照个人所得税法,居民个人从中国境内和境外取得的所得均应依法缴纳个人所得税。有境外所得的纳税人,须就境内外全部所得在6月底前完成申报。税务部门将利用国际间金融账户涉税信息自动交换(CRS)等信息数据,对境外所得申报数据进行分析比对,持续加强税收监管。 来源:第一财经
税务总局:已有7000万纳税人申请退还个税
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
爱投资的小熊猫
·
01-22
新华社官媒已经定调,CRS问题一定一定要开始重视了!crs相关问题第三期
前面两篇主要针对群里朋友们分享了的CRS一些问题,进行了归纳总结,相信大家也有了一些收获。 前几天的新闻,现在就连官方媒体新华社都在报告境外纳税的新闻了,我对这块还没有概念的朋友要一定一定要开始重视了,就连官媒都发声了,千万别再觉得这个事情不重要。 最近也看到不少群友在讨论怎样少交或者不交的问题。今天的话也想给大家聊聊这个事儿。 首先需要明确的是,面对CRS我们不要想着怎么去逃,而是要积极主动的面对。如果你的海外收入不多,就尽快地去把这个事情解决掉,自己也好安心。当然针对存疑的部分,该拿出证据来解释还是有必要的。禾兑局也是依法办事,不会是刻意为难我们。 但是如果你的等资产到了一定量级了,那需要考虑的问题不单单是“交”或者“不交”的问题了。这个时候我们要想得更多更远。 看有人说“我愿意交禾兑,但我怕交完禾兑还有坑”。是的,这才是让人焦虑的根本原因。 真正让人睡不着的,从来不是“交禾兑”这两个字。 最近和几位资产规模已经上台阶的朋友聊天,他们反复提到一个观点——当资产积累到一定程度后,最让人辗转反侧的,从来不是“要不要交禾兑”“交多少禾兑”,而是“合不合规”。 这话是不是好像有点反常识,但是仔细想却特别戳中要害。就像自己买个名牌包,真正在意的不是价格,而是怕买到假货、怕售后没保障;对高净值人群来说,资产的“合规性”,才是他们最在意的“安全底线”。 他们真正怕的是啥?是“交完禾兑之后,会不会还有其他问题”。比如: 钱的“来路”是不是干净? 有些朋友早些年创业,可能有些账目没那么规范,或者有些收入没完全报税——现在想合规了,把这些补上没问题,但补完之后会不会被“翻旧账”?会不会因为以前的不规范,影响现在的资产安全? 钱“出境”合不合规? 想把钱转到海外做投资、给孩子交学费,或者配置海外资产,这本身没问题。但万一转钱的方式没走对渠道,哪怕税交了,会不会被海关、
新华社官媒已经定调,CRS问题一定一定要开始重视了!crs相关问题第三期
精彩
zhirong66:
最近网传华美➕盈透完美避,不知道是不是真的
回复
1
点赞
1
编组 21备份 2
分享
举报
爱投资的小熊猫
·
01-07
CRS真来了,也不要惊慌失措,群友相关问题的答疑,第一期
最近一段时间,WX上面咨询关于CRS的问题的朋友也越来越多了,说明大家也越来越重视这个问题了,确实有关于CRS迫在眉睫,是我们必须要重视起来的一个问题。 在讲这个crs问题之前,我们先说另一个内容,讲讲一个ETFCNQQ! 新年伊始,美股三大指数接连刷新历史新高、A股沪指站上十年高位,在这双重牛市背景下,大家该如何投资才能把握这个机会呢? 记得之前在文章里提到CNQQ这个A+H中概硬科技的跨境ETF吗?目前已涨超5%了,涨幅虽然不大,但很稳健。 这只上市仅3个多月的跨境ETF,既承接了市场红利的正向催化,又凭借差异化的产品设计展现出独特的投资价值,其背后的配置逻辑与实操策略,值得投资者深入解读。 CNQQ的核心竞争力,根植于其差异化的产品内核。其指数编制跳出了单纯的市值加权逻辑,将企业过去三年研发支出占比纳入核心筛选因子,结合总市值与流通市值计算调整后市值,精选103家创新型科技企业,且单只成份股权重上限严格控制在10%,每半年一次的再平衡既规避了个股集中风险,又能通过纪律性调仓捕捉低估机会。在持仓结构上,CNQQ构建了“互联网龙头+硬科技先锋”的多元布局,前十大重仓既包含腾讯、阿里等互联网巨头,也囊括宁德时代、中际旭创、北方华创等半导体、新能源领域的硬科技龙头,行业覆盖汽车交通、电子电气、工业制造等五大核心赛道。与科创50ETF高度集中半导体的结构相比,CNQQ更显均衡;而相较于KWEB等侧重海外中概互联网的产品,CNQQ完全聚焦A+H本土科技力量,成为美股市场中稀缺的中国硬科技“打包”工具。 在当前市场环境下,CNQQ的投资价值被进一步放大。其一,A+H科技资产的双牛共振形成了强劲的基本面支撑:CNQQ持仓中55%的A股硬科技标的直接受益于A股科技赛道的结构性行情,半导体、新能源等领域的政策红利与资金流入持续传导;45%的港股科技成分则随A股回暖同步修复,而美股创新高的
CRS真来了,也不要惊慌失措,群友相关问题的答疑,第一期
回复
评论
点赞
1
编组 21备份 2
分享
举报
招财部落
·
2025-11-24
买买买!外资大药厂再次出手中国Biotech
今天一早,港股创新药企和铂医药发布公告,与阿斯利康基于3月21日的合作协议共同修订合作协议,共同发现和开发包括抗体偶联药物(ADC)和T细胞衔接器(TCE)在内的新一代生物疗法,这是阿斯利康与和铂医药的进一步深度绑定。 阿斯利康已经多次出手和铂医药了: 1)2022年Claudin18.2/CD3双抗的全球授权(2500万美元预付款+3.25亿美元里程碑+外加销售分成); 2)2024年5月一款临床前单抗项目的授权(1900万美元预付款+1000万美元近期里程碑+5.75亿美元里程碑+外加销售分成); 3)2025年3月21日两项临床前免疫学项目的授权许以及多个项目的选择权(1.75亿美元首付款、近期里程碑付款及选择权行权费,最高达44亿美元的里程碑付款以及销售分成)。同时,阿斯利康以1.05亿美元认购和铂医药9.15%的新发行股份,当天收盘价溢价37.2%。 今天的重新修订的合作协议将合作范围扩大到抗体偶联药物(ADC)和T细胞衔接器(TCE),必然是基于对和铂研发平台的高度认可,和铂医药也表示将有资格获得选择权费、开发与商业里程碑付款,以及未来的销售分成。 作为阿斯利康明确加码的技术,和铂医药全人源HBICE®双抗技术及HarbourMice®平台立了大功。 和铂基于此平台研发出来的T细胞衔接器(TCE)已经卖了三笔BD交易: 1)2022年4月与阿斯利康达成的超过3.5亿美元的Claudin18.2/CD3双抗;2)2024年12月与Candid达成的3.2亿美元的T细胞连接器的研究合作及授权协议;3)2025年6月,用于治疗自身免疫疾病的BCMA/CD3双特异性HBM7020将海外权益卖给了大冢制药,获得4700万美元首付款及近期付款+6.23亿潜在里程碑付款(合计约48亿人民币),以及未来的销售分成。 T细胞衔接器(TCE)优势很明显,它是一种特殊双抗,一端连接T
买买买!外资大药厂再次出手中国Biotech
回复
评论
点赞
1
编组 21备份 2
分享
举报
ETF小帮手
·
2025-07-02
💰小盘股IWM站上200日均线:降息、周期交替+减税预期,2025下半年看涨!
$罗素2000指数ETF(IWM)$
在2025年下半年第一个交易日站上重要的 200MA均线,属实是一个好的开端。截至2025年7月1日,IWM上涨,从4月8日低点反弹27%。年初至今表现为-1.34%。小虎们,2025年上半年,你有交易什么小盘股吗?欢迎评论区晒单。[梭哈]
$罗素2000指数ETF(IWM)$
的十大成分股是
$Sprouts Farmers Market Inc(SFM)$
,
$Insmed(INSM)$
,
$FTAI AVIATION LTD(FTAI)$
,
$Credo Technology Group Holding Ltd(CRDO)$
,
$Fabrinet(FN)$
,
$IONQ Inc.(IONQ)$
;
$Hims & Hers Health Inc.(HIMS)$
,
$卡朋特科技(CRS)$
,
💰小盘股IWM站上200日均线:降息、周期交替+减税预期,2025下半年看涨!
回复
评论
点赞
4
编组 21备份 2
分享
举报
钛媒体APP
·
2025-01-13
自免TCE开始有人掉队了
文 | 氨基观察 2024年以来,自免领域的TCE彻底火了。 海外大药企持续押注该领域,国产TCE也随之坐上了风口,诞生了国内Biotech出海史上两项价值巨大的交易,包括同润生物和默沙东达成CD3/CD19双抗的收购,合作首付款为7亿美元,仅次于BMS与百利天恒关于双抗ADC的合作; 以及GSK收购恩沐生物的CD3/CD19/CD20三抗CMG1A46的合作,交易首付款为3亿美元,也是较高的水平。 自免TCE的大火是事实,但不可否认,这一领域也充满了未知数。 1月10日,从肿瘤转型自免的IGM Biosciences,就遭遇了打击:核心管线CD20xCD3双抗IGM-2323在自免领域展现的B细胞耗竭深度让人失望。 IGM不得不终止IGM-2323的研发,以及另一款TCE IGM-2644也被迫终止。原因在于,两款TCE的设计思路相同,都采用IgM抗体。但从IGM-2323的表现来看,成功概率可能不大。 失败的消息,让IGM的股价大跌近70%,市值只剩下1.24亿美元。 IGM的遭遇不会是普遍现象。但一定程度上,它如同风向标指明一件事——这个黄金赛道,注定会冰火两重天,火爆的同时,掉队者也会持续出现。 放弃肿瘤,押注自免 过去几年,在自免的热潮下,许多专注于肿瘤研发的biotech,因为各种原因转道自免赛道。IGM也正是这样一家公司。 作为曾经的明星肿瘤biotech,IGM辉煌过,市值曾经超过60亿美金。但随着临床研究的不尽如人意,以及与赛诺菲等重磅合作伙伴的分道扬镳,迫使它做出战略选择。 2023年12月,面对持续减少的现金,IGM开始转向:放弃血液瘤的研发,进入自免领域。 彼时,IGM手中的两款TCE,CD20xCD3双抗IGM-2323、CD38xCD3双抗IGM-2644均在血液瘤领域进行探索,前者针对非霍奇金淋巴瘤,后者针对多发性骨髓瘤。 但IGM决定停止两款
自免TCE开始有人掉队了
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
锦缎
·
2024-10-29
小细胞肺癌,长夜渐明
肺癌是人类“头号杀手”,而在肺癌的诸多类型中,小细胞肺癌(SCLC)又是预后最差的。之所以SCLC预后很差,主要是由两点原因造成的:生长速度快、恶性程度高。SCLC生长速度极快,如果检查不及时,就很容贻误病情;同时SCLC恶性度高,对癌肿周围组织及重要血管极易侵犯。这就导致大多数SCLC患者确诊时都已经处于广泛期(扩散到身体其他部位的侵袭性类型),甚至约 50% 的患者将发生脑转移。SCLC的预后到底有多差呢?患者的5年总生存率仅为 5%~10%,广泛期SCLC(ES-SCLC)患者的中位OS范围仅为12个月左右。虽然SCLC在肺癌总占比并不高,约为15%,但其背后却影响的是全球37.2万名患者的生命。冷冰冰的数字,透露出患者对SCLC新疗法的迫切,现有疗法存在极大的未满足需求。暗夜长空中,透露出一股暖光。在10月24日巴塞罗那举行的2024年EORTC-NCI-AACR(ENA)大会上,再鼎医药以全体会议口头报告的形式,公布了正在进行的ZL-1310全球1a期临床研究数据,在复发的广泛期小细胞肺癌(SCLC)患者中,ZL-1310在所有测试剂量水平的客观缓解率(ORR)达74%。尽管ZL-1310仅处于临床早期,但74%的ORR还是明显超过唯一获批二线靶向疗法Tarlatamab 40%的ORR数据。这是SCLC领域一次新的突破,只要后续ZL-1310进展顺利,那么它极有可能成为SCLC的核心疗法,甚至有望与PD-1联用成为SCLC的一线疗法。一场颠覆,或在悄然发生。01远未满足的SCLC需求依据肿瘤进展情况,SCLC共可分为两大类:局限期SCLC(LS-SCLC)和广泛期SCLC(ES-SCLC)。LS-SCLC,指病变限于一侧胸腔,且能被纳入一个放射治疗野内,对应TNM分期I-III期;ES-SCLC,指病变超过一侧胸腔,且包括恶性胸腔和心包积液或血行转移,对应TNM
小细胞肺癌,长夜渐明
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
美股投资网
·
2024-07-23
特朗普交易:这10只美股蓄势待发
随着2024年美国总统大选结果的临近,美国政.治.局势的变化正在引发金融市场高度关注。特朗普在竞选遭遇枪击事件,短期内,他可能会获得一些同情分,美国大选经验表明,得摇摆州者得白宫。2024年大选,特朗普在7大摇摆州的民调显著领先。 华尔街分析师开始评估“特朗普交易”可能带来的影响。特朗普的2024年提案和平台呼吁现代化军队、提升国内制造业,并使美国成为全球主导的能源生产国。一些分析师认为,特朗普的税改和放松监管议程开始在市场中体现出来,这会利好金融行业并预计会下发更多并购标准。
$英伟达(NVDA)$
$苹果(AAPL)$
BNP Paribas宏观策略主管Calvin Tse指出:“特朗普交易是一种美国利率曲线陡峭化的策略。特朗普的证策大体上是通胀性的(关税、更宽松的财证证策),与此同时,他可能会任命一位更偏向鸽派的美联储主席。在上周的辩论之后,利率曲线在周五和周一都变得更加陡峭——这可能反映了特朗普获胜的概率上升。” 10 年期减 3 个月国债: 我们关注到有十只“特朗普交易潜力股”,横跨国防、科技、金融等热门板块。这些股票紧密关联特朗普2.0证府可能推行的证策方向,预示着巨大的增长潜力。 01 第一只工业股:Carpenter Technology Corporation(CRS)
$卡朋特科技(CRS)$
是一家领先的高性能特种合金制造商,拥有超过130年的冶金和制造专业知识,专注于生产高性能的特殊金属和合金,包括钛合金和不锈钢。其产品广泛用于航空航天、国防和能源等关键领域。 CRS在截至5月3日的一周内成为最大的工业类股票,涨幅为
特朗普交易:这10只美股蓄势待发
精彩
快乐金生:
我20年10月买的这个股票, 现在亏87%
回复
6
点赞
8
编组 21备份 2
分享
举报
格鲁1498
·
2024-07-17
特朗普10家相关概念股,都可以加自选看看:[可爱]
$Rumble Inc.(RUM)$
$Palantir Technologies Inc.(PLTR)$
$Coinbase Global, Inc.(COIN)$
$卡朋特科技(CRS)$
$特朗普媒体科技集团(DJT)$
$Phunware, Inc.(PHUN)$
$Argan Inc.(AGX)$
$哈里斯公司(LHX)$
$Western Midstream Operating, LP.(WES)$
$特斯拉(TSLA)$
懂王说在大选之前最好不要降息,并说“不会fire鲍威尔”,看来对鲍威尔近期比较鸽派的言论还是满意的,大选前市场看涨[看涨]
特朗普10家相关概念股,都可以加自选看看:[可爱] $Rumble Inc.(RUM)$ $Palantir Technologies Inc.(PLTR...
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
卡朋特科技
所属市场
NYSE
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.carpentertechnology.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Carpenter Technology Corporation成立于1889年,是特拉华州的一家公司。该公司从事特种金属的制造和分销。该公司是优质特种合金的生产商和分销商,包括钛合金、粉末金属、不锈钢、合金钢和工具钢。在航空航天、国防、医疗、运输、能源、工业和消费市场的关键应用领域,该公司是公认的高性能特种合金材料和工艺解决方案的领导者。该公司已经发展成为优质特种合金的先驱,包括钛、镍和钴,以及专门为增材制造工艺和软磁应用设计的合金。
02-24
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
02-20
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
02-19
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
02-18
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
01-29
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01-29
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
01-29
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-12-11
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
2025-12-10
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
2025-12-09
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
2025-11-26
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
2025-11-21
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
2025-11-20
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-11-11
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-11-10
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
分时
5日
日
周
月
数据加载中...
最高
407.03
今开
391.32
量比
0.51
最低
386.40
昨收
404.32
换手率
1.03%
热议股票
{"pagemeta":{"title":"卡朋特科技(CRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供卡朋特科技(CRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"卡朋特科技,CRS,卡朋特科技股票,卡朋特科技股票老虎,卡朋特科技股票老虎国际,卡朋特科技行情,卡朋特科技股票行情,卡朋特科技股价,卡朋特科技股市,卡朋特科技股票价格,卡朋特科技股票交易,卡朋特科技股票购买,卡朋特科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"卡朋特科技(CRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供卡朋特科技(CRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"CRS","data":{"stockData":{"symbol":"CRS","market":"US","secType":"STK","nameCN":"卡朋特科技","latestPrice":391.51,"timestamp":1775160000000,"preClose":404.32,"halted":0,"volume":500946,"hourTrading":{"tag":"盘后","latestPrice":395.99,"preClose":391.51,"latestTime":"19:58 EDT","volume":13095,"amount":5128370.59,"timestamp":1775174303535,"change":4.48,"changeRate":0.011443,"amplitude":0.011443},"delay":0,"changeRate":-0.031682825484764546,"floatShares":48497746,"shares":49818822,"eps":8.608724,"marketStatus":"耶稣受难日休市","change":-12.81,"latestTime":"04-02 16:00:00 EDT","open":391.32,"high":407.03,"low":386.4,"amount":198020697.651,"amplitude":0.051024,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":8.608724,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":404.32,"dividendRate":0.002043,"preHourTrading":{"tag":"盘前","latestPrice":392,"preClose":404.32,"latestTime":"09:22 EDT","volume":1611,"amount":635841.0792,"timestamp":1775136169646,"change":-12.32,"changeRate":-0.030471,"amplitude":0.02221},"postHourTrading":{"tag":"盘后","latestPrice":395.99,"preClose":391.51,"latestTime":"19:58 EDT","volume":13095,"amount":5128370.59,"timestamp":1775174303535,"change":4.48,"changeRate":0.011443,"amplitude":0.011443},"volumeRatio":0.5076912045270402,"impliedVol":0.5957,"impliedVolPercentile":0.9283},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.548968365622448","cardData":[{"tweetId":"548968365622448","author":{"authorId":"4229659782866940","idStr":"4229659782866940","name":"今朝新闻","avatar":"https://static.tigerbbs.com/4bb05c87c4017404d2f69bb1bcebecd7","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"税务总局:已有7000万纳税人申请退还个税","digest":"4月1日,国家税务总局政策法规司司长戴诗友在税务总局新闻发布会上表示,今年个税汇算已进行了一个月,超过7000万纳税人已依法申请退税,还有超过500万纳税人自行依法申报补税,整体运行平稳有序。 戴诗友表示,个税汇算办理时间将持续至6月30日,请大家合理安排时间、错峰申报,尽量避开6月底高峰期。可以退税的纳税人抓紧领取退税“红包”;需要补税的纳税人,请在规定时间内申报并补缴税款,避免逾期产生滞纳金,造成不必要的损失。 他提醒,按照个人所得税法,居民个人从中国境内和境外取得的所得均应依法缴纳个人所得税。有境外所得的纳税人,须就境内外全部所得在6月底前完成申报。税务部门将利用国际间金融账户涉税信息自动交换(CRS)等信息数据,对境外所得申报数据进行分析比对,持续加强税收监管。 来源:第一财经","plainDigest":"4月1日,国家税务总局政策法规司司长戴诗友在税务总局新闻发布会上表示,今年个税汇算已进行了一个月,超过7000万纳税人已依法申请退税,还有超过500万纳税人自行依法申报补税,整体运行平稳有序。 戴诗友表示,个税汇算办理时间将持续至6月30日,请大家合理安排时间、错峰申报,尽量避开6月底高峰期。可以退税的纳税人抓紧领取退税“红包”;需要补税的纳税人,请在规定时间内申报并补缴税款,避免逾期产生滞纳金,造成不必要的损失。 他提醒,按照个人所得税法,居民个人从中国境内和境外取得的所得均应依法缴纳个人所得税。有境外所得的纳税人,须就境内外全部所得在6月底前完成申报。税务部门将利用国际间金融账户涉税信息自动交换(CRS)等信息数据,对境外所得申报数据进行分析比对,持续加强税收监管。 来源:第一财经","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1775047318122,"gmtModify":1775047323748,"symbols":["CRS"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":145,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/548968365622448","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":642,"displayRows":4,"foldSize":0,"authorId":"4229659782866940"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.524469535064544","cardData":[{"tweetId":"524469535064544","author":{"authorId":"3468677072884748","idStr":"3468677072884748","name":"爱投资的小熊猫","avatar":"https://static.tigerbbs.com/161807d4571cc1775f29fd24a2eaac9c","userType":1,"introduction":"","crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5321,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"新华社官媒已经定调,CRS问题一定一定要开始重视了!crs相关问题第三期","digest":"前面两篇主要针对群里朋友们分享了的CRS一些问题,进行了归纳总结,相信大家也有了一些收获。 前几天的新闻,现在就连官方媒体新华社都在报告境外纳税的新闻了,我对这块还没有概念的朋友要一定一定要开始重视了,就连官媒都发声了,千万别再觉得这个事情不重要。 最近也看到不少群友在讨论怎样少交或者不交的问题。今天的话也想给大家聊聊这个事儿。 首先需要明确的是,面对CRS我们不要想着怎么去逃,而是要积极主动的面对。如果你的海外收入不多,就尽快地去把这个事情解决掉,自己也好安心。当然针对存疑的部分,该拿出证据来解释还是有必要的。禾兑局也是依法办事,不会是刻意为难我们。 但是如果你的等资产到了一定量级了,那需要考虑的问题不单单是“交”或者“不交”的问题了。这个时候我们要想得更多更远。 看有人说“我愿意交禾兑,但我怕交完禾兑还有坑”。是的,这才是让人焦虑的根本原因。 真正让人睡不着的,从来不是“交禾兑”这两个字。 最近和几位资产规模已经上台阶的朋友聊天,他们反复提到一个观点——当资产积累到一定程度后,最让人辗转反侧的,从来不是“要不要交禾兑”“交多少禾兑”,而是“合不合规”。 这话是不是好像有点反常识,但是仔细想却特别戳中要害。就像自己买个名牌包,真正在意的不是价格,而是怕买到假货、怕售后没保障;对高净值人群来说,资产的“合规性”,才是他们最在意的“安全底线”。 他们真正怕的是啥?是“交完禾兑之后,会不会还有其他问题”。比如: 钱的“来路”是不是干净? 有些朋友早些年创业,可能有些账目没那么规范,或者有些收入没完全报税——现在想合规了,把这些补上没问题,但补完之后会不会被“翻旧账”?会不会因为以前的不规范,影响现在的资产安全? 钱“出境”合不合规? 想把钱转到海外做投资、给孩子交学费,或者配置海外资产,这本身没问题。但万一转钱的方式没走对渠道,哪怕税交了,会不会被海关、","plainDigest":"前面两篇主要针对群里朋友们分享了的CRS一些问题,进行了归纳总结,相信大家也有了一些收获。 前几天的新闻,现在就连官方媒体新华社都在报告境外纳税的新闻了,我对这块还没有概念的朋友要一定一定要开始重视了,就连官媒都发声了,千万别再觉得这个事情不重要。 最近也看到不少群友在讨论怎样少交或者不交的问题。今天的话也想给大家聊聊这个事儿。 首先需要明确的是,面对CRS我们不要想着怎么去逃,而是要积极主动的面对。如果你的海外收入不多,就尽快地去把这个事情解决掉,自己也好安心。当然针对存疑的部分,该拿出证据来解释还是有必要的。禾兑局也是依法办事,不会是刻意为难我们。 但是如果你的等资产到了一定量级了,那需要考虑的问题不单单是“交”或者“不交”的问题了。这个时候我们要想得更多更远。 看有人说“我愿意交禾兑,但我怕交完禾兑还有坑”。是的,这才是让人焦虑的根本原因。 真正让人睡不着的,从来不是“交禾兑”这两个字。 最近和几位资产规模已经上台阶的朋友聊天,他们反复提到一个观点——当资产积累到一定程度后,最让人辗转反侧的,从来不是“要不要交禾兑”“交多少禾兑”,而是“合不合规”。 这话是不是好像有点反常识,但是仔细想却特别戳中要害。就像自己买个名牌包,真正在意的不是价格,而是怕买到假货、怕售后没保障;对高净值人群来说,资产的“合规性”,才是他们最在意的“安全底线”。 他们真正怕的是啥?是“交完禾兑之后,会不会还有其他问题”。比如: 钱的“来路”是不是干净? 有些朋友早些年创业,可能有些账目没那么规范,或者有些收入没完全报税——现在想合规了,把这些补上没问题,但补完之后会不会被“翻旧账”?会不会因为以前的不规范,影响现在的资产安全? 钱“出境”合不合规? 想把钱转到海外做投资、给孩子交学费,或者配置海外资产,这本身没问题。但万一转钱的方式没走对渠道,哪怕税交了,会不会被海关、","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1769057922521,"gmtModify":1769059052685,"symbols":["CRS"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":3,"images":[{"url":"https://static.tigerbbs.com/6bb81ecff3d436e01663e00bfcbf3eb8","width":"222","height":"751"}],"repostCount":0,"viewCount":2317,"likeCount":1,"liked":false,"collected":false,"commentCount":1,"hotComments":[{"id":"525489506947432","author":{"authorId":"3487395659107020","idStr":"3487395659107020","name":"zhirong66","avatar":"https://static.tigerbbs.com/6dc5fc6c5435052ad8796fde03864dd3","userType":1,"introduction":"","crmLevel":5,"crmLevelSwitch":0,"fanSize":101,"starInvestorFlag":false},"content":"最近网传华美➕盈透完美避,不知道是不是真的","plainContent":"最近网传华美➕盈透完美避,不知道是不是真的","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/524469535064544","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4245,"displayRows":4,"foldSize":0,"authorId":"3468677072884748"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.519280588399024","cardData":[{"tweetId":"519280588399024","author":{"authorId":"3468677072884748","idStr":"3468677072884748","name":"爱投资的小熊猫","avatar":"https://static.tigerbbs.com/161807d4571cc1775f29fd24a2eaac9c","userType":1,"introduction":"","crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5321,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"CRS真来了,也不要惊慌失措,群友相关问题的答疑,第一期","digest":"最近一段时间,WX上面咨询关于CRS的问题的朋友也越来越多了,说明大家也越来越重视这个问题了,确实有关于CRS迫在眉睫,是我们必须要重视起来的一个问题。 在讲这个crs问题之前,我们先说另一个内容,讲讲一个ETFCNQQ! 新年伊始,美股三大指数接连刷新历史新高、A股沪指站上十年高位,在这双重牛市背景下,大家该如何投资才能把握这个机会呢? 记得之前在文章里提到CNQQ这个A+H中概硬科技的跨境ETF吗?目前已涨超5%了,涨幅虽然不大,但很稳健。 这只上市仅3个多月的跨境ETF,既承接了市场红利的正向催化,又凭借差异化的产品设计展现出独特的投资价值,其背后的配置逻辑与实操策略,值得投资者深入解读。 CNQQ的核心竞争力,根植于其差异化的产品内核。其指数编制跳出了单纯的市值加权逻辑,将企业过去三年研发支出占比纳入核心筛选因子,结合总市值与流通市值计算调整后市值,精选103家创新型科技企业,且单只成份股权重上限严格控制在10%,每半年一次的再平衡既规避了个股集中风险,又能通过纪律性调仓捕捉低估机会。在持仓结构上,CNQQ构建了“互联网龙头+硬科技先锋”的多元布局,前十大重仓既包含腾讯、阿里等互联网巨头,也囊括宁德时代、中际旭创、北方华创等半导体、新能源领域的硬科技龙头,行业覆盖汽车交通、电子电气、工业制造等五大核心赛道。与科创50ETF高度集中半导体的结构相比,CNQQ更显均衡;而相较于KWEB等侧重海外中概互联网的产品,CNQQ完全聚焦A+H本土科技力量,成为美股市场中稀缺的中国硬科技“打包”工具。 在当前市场环境下,CNQQ的投资价值被进一步放大。其一,A+H科技资产的双牛共振形成了强劲的基本面支撑:CNQQ持仓中55%的A股硬科技标的直接受益于A股科技赛道的结构性行情,半导体、新能源等领域的政策红利与资金流入持续传导;45%的港股科技成分则随A股回暖同步修复,而美股创新高的","plainDigest":"最近一段时间,WX上面咨询关于CRS的问题的朋友也越来越多了,说明大家也越来越重视这个问题了,确实有关于CRS迫在眉睫,是我们必须要重视起来的一个问题。 在讲这个crs问题之前,我们先说另一个内容,讲讲一个ETFCNQQ! 新年伊始,美股三大指数接连刷新历史新高、A股沪指站上十年高位,在这双重牛市背景下,大家该如何投资才能把握这个机会呢? 记得之前在文章里提到CNQQ这个A+H中概硬科技的跨境ETF吗?目前已涨超5%了,涨幅虽然不大,但很稳健。 这只上市仅3个多月的跨境ETF,既承接了市场红利的正向催化,又凭借差异化的产品设计展现出独特的投资价值,其背后的配置逻辑与实操策略,值得投资者深入解读。 CNQQ的核心竞争力,根植于其差异化的产品内核。其指数编制跳出了单纯的市值加权逻辑,将企业过去三年研发支出占比纳入核心筛选因子,结合总市值与流通市值计算调整后市值,精选103家创新型科技企业,且单只成份股权重上限严格控制在10%,每半年一次的再平衡既规避了个股集中风险,又能通过纪律性调仓捕捉低估机会。在持仓结构上,CNQQ构建了“互联网龙头+硬科技先锋”的多元布局,前十大重仓既包含腾讯、阿里等互联网巨头,也囊括宁德时代、中际旭创、北方华创等半导体、新能源领域的硬科技龙头,行业覆盖汽车交通、电子电气、工业制造等五大核心赛道。与科创50ETF高度集中半导体的结构相比,CNQQ更显均衡;而相较于KWEB等侧重海外中概互联网的产品,CNQQ完全聚焦A+H本土科技力量,成为美股市场中稀缺的中国硬科技“打包”工具。 在当前市场环境下,CNQQ的投资价值被进一步放大。其一,A+H科技资产的双牛共振形成了强劲的基本面支撑:CNQQ持仓中55%的A股硬科技标的直接受益于A股科技赛道的结构性行情,半导体、新能源等领域的政策红利与资金流入持续传导;45%的港股科技成分则随A股回暖同步修复,而美股创新高的","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1767752269984,"gmtModify":1767753360247,"symbols":["CRS"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":5,"images":[{"url":"https://static.tigerbbs.com/4fce83eec1ee07c9a7aeac540416688b","width":"957","height":"500"}],"repostCount":0,"viewCount":3145,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/519280588399024","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":6693,"displayRows":4,"foldSize":0,"authorId":"3468677072884748"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.504331591962792","cardData":[{"tweetId":"504331591962792","author":{"authorId":"3460273557341904","idStr":"3460273557341904","name":"招财部落","avatar":"https://static.tigerbbs.com/b94b67d3d0802293e37b868040c3b448","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":50,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"买买买!外资大药厂再次出手中国Biotech","digest":"今天一早,港股创新药企和铂医药发布公告,与阿斯利康基于3月21日的合作协议共同修订合作协议,共同发现和开发包括抗体偶联药物(ADC)和T细胞衔接器(TCE)在内的新一代生物疗法,这是阿斯利康与和铂医药的进一步深度绑定。 阿斯利康已经多次出手和铂医药了: 1)2022年Claudin18.2/CD3双抗的全球授权(2500万美元预付款+3.25亿美元里程碑+外加销售分成); 2)2024年5月一款临床前单抗项目的授权(1900万美元预付款+1000万美元近期里程碑+5.75亿美元里程碑+外加销售分成); 3)2025年3月21日两项临床前免疫学项目的授权许以及多个项目的选择权(1.75亿美元首付款、近期里程碑付款及选择权行权费,最高达44亿美元的里程碑付款以及销售分成)。同时,阿斯利康以1.05亿美元认购和铂医药9.15%的新发行股份,当天收盘价溢价37.2%。 今天的重新修订的合作协议将合作范围扩大到抗体偶联药物(ADC)和T细胞衔接器(TCE),必然是基于对和铂研发平台的高度认可,和铂医药也表示将有资格获得选择权费、开发与商业里程碑付款,以及未来的销售分成。 作为阿斯利康明确加码的技术,和铂医药全人源HBICE®双抗技术及HarbourMice®平台立了大功。 和铂基于此平台研发出来的T细胞衔接器(TCE)已经卖了三笔BD交易: 1)2022年4月与阿斯利康达成的超过3.5亿美元的Claudin18.2/CD3双抗;2)2024年12月与Candid达成的3.2亿美元的T细胞连接器的研究合作及授权协议;3)2025年6月,用于治疗自身免疫疾病的BCMA/CD3双特异性HBM7020将海外权益卖给了大冢制药,获得4700万美元首付款及近期付款+6.23亿潜在里程碑付款(合计约48亿人民币),以及未来的销售分成。 T细胞衔接器(TCE)优势很明显,它是一种特殊双抗,一端连接T","plainDigest":"今天一早,港股创新药企和铂医药发布公告,与阿斯利康基于3月21日的合作协议共同修订合作协议,共同发现和开发包括抗体偶联药物(ADC)和T细胞衔接器(TCE)在内的新一代生物疗法,这是阿斯利康与和铂医药的进一步深度绑定。 阿斯利康已经多次出手和铂医药了: 1)2022年Claudin18.2/CD3双抗的全球授权(2500万美元预付款+3.25亿美元里程碑+外加销售分成); 2)2024年5月一款临床前单抗项目的授权(1900万美元预付款+1000万美元近期里程碑+5.75亿美元里程碑+外加销售分成); 3)2025年3月21日两项临床前免疫学项目的授权许以及多个项目的选择权(1.75亿美元首付款、近期里程碑付款及选择权行权费,最高达44亿美元的里程碑付款以及销售分成)。同时,阿斯利康以1.05亿美元认购和铂医药9.15%的新发行股份,当天收盘价溢价37.2%。 今天的重新修订的合作协议将合作范围扩大到抗体偶联药物(ADC)和T细胞衔接器(TCE),必然是基于对和铂研发平台的高度认可,和铂医药也表示将有资格获得选择权费、开发与商业里程碑付款,以及未来的销售分成。 作为阿斯利康明确加码的技术,和铂医药全人源HBICE®双抗技术及HarbourMice®平台立了大功。 和铂基于此平台研发出来的T细胞衔接器(TCE)已经卖了三笔BD交易: 1)2022年4月与阿斯利康达成的超过3.5亿美元的Claudin18.2/CD3双抗;2)2024年12月与Candid达成的3.2亿美元的T细胞连接器的研究合作及授权协议;3)2025年6月,用于治疗自身免疫疾病的BCMA/CD3双特异性HBM7020将海外权益卖给了大冢制药,获得4700万美元首付款及近期付款+6.23亿潜在里程碑付款(合计约48亿人民币),以及未来的销售分成。 T细胞衔接器(TCE)优势很明显,它是一种特殊双抗,一端连接T","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1763993580000,"gmtModify":1764146777376,"symbols":["CRS","LU0963586101.USD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","LU2065731478.USD","02142","IE00B7SZL793.SGD","IE0031619046.USD","ADC"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":4,"images":[{"url":"https://static.tigerbbs.com/330b23a5554e4011b9b9af06b1f5f1f5"},{"url":"https://static.tigerbbs.com/5c5dc67d742340d8a08c4b3cab5a3725"},{"url":"https://static.tigerbbs.com/2587a0b929104a27832584f0c2a886de"}],"repostCount":0,"viewCount":1752,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/504331591962792","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3024,"displayRows":4,"foldSize":0,"authorId":"3460273557341904"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.452295532146832","cardData":[{"tweetId":"452295532146832","author":{"authorId":"3527667688472228","idStr":"3527667688472228","name":"ETF小帮手","avatar":"https://static.tigerbbs.com/087e050021c7db2ae39b1cb7515b694d","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4572,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"💰小盘股IWM站上200日均线:降息、周期交替+减税预期,2025下半年看涨!","digest":"<a href=\"https://laohu8.com/S/IWM\">$罗素2000指数ETF(IWM)$</a> 在2025年下半年第一个交易日站上重要的 200MA均线,属实是一个好的开端。截至2025年7月1日,IWM上涨,从4月8日低点反弹27%。年初至今表现为-1.34%。小虎们,2025年上半年,你有交易什么小盘股吗?欢迎评论区晒单。[梭哈]<a href=\"https://laohu8.com/S/IWM\">$罗素2000指数ETF(IWM)$</a> 的十大成分股是 <a href=\"https://laohu8.com/S/SFM\">$Sprouts Farmers Market Inc(SFM)$</a> , <a href=\"https://laohu8.com/S/INSM\">$Insmed(INSM)$</a> , <a href=\"https://laohu8.com/S/FTAI\">$FTAI AVIATION LTD(FTAI)$</a> , <a href=\"https://laohu8.com/S/CRDO\">$Credo Technology Group Holding Ltd(CRDO)$</a> , <a href=\"https://laohu8.com/S/FN\">$Fabrinet(FN)$</a> , <a href=\"https://laohu8.com/S/IONQ\">$IONQ Inc.(IONQ)$</a> ; <a href=\"https://laohu8.com/S/HIMS\">$Hims & Hers Health Inc.(HIMS)$</a> , <a href=\"https://laohu8.com/S/CRS\">$卡朋特科技(CRS)$</a> ,","plainDigest":"$罗素2000指数ETF(IWM)$ 在2025年下半年第一个交易日站上重要的 200MA均线,属实是一个好的开端。截至2025年7月1日,IWM上涨,从4月8日低点反弹27%。年初至今表现为-1.34%。小虎们,2025年上半年,你有交易什么小盘股吗?欢迎评论区晒单。[梭哈]$罗素2000指数ETF(IWM)$ 的十大成分股是 $Sprouts Farmers Market Inc(SFM)$ , $Insmed(INSM)$ , $FTAI AVIATION LTD(FTAI)$ , $Credo Technology Group Holding Ltd(CRDO)$ , $Fabrinet(FN)$ , $IONQ Inc.(IONQ)$ ; $Hims & Hers Health Inc.(HIMS)$ , $卡朋特科技(CRS)$ ,","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1751428867547,"gmtModify":1751438144875,"symbols":["CRS","FTAI","MS","CRDO","HIMS","FN","MLI","SFM","IONQ","AIT","INSM","IWM"],"themeIds":["fb0b8a84b3ed43f49e4a9bb328a89463"],"popularizeThemeFlag":false,"imageCount":2,"images":[{"url":"https://static.tigerbbs.com/2c4ba40e56bbee25251ad94894451236"}],"repostCount":1,"viewCount":19737,"likeCount":4,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/452295532146832","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":true,"upFlag":false,"length":3948,"displayRows":4,"foldSize":0,"authorId":"3527667688472228"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.392175303180744","cardData":[{"tweetId":"392175303180744","author":{"authorId":"3574917796328560","idStr":"3574917796328560","name":"钛媒体APP","avatar":"https://static.tigerbbs.com/a30e6edce861fd1d3d0c1268a2d83b40","userType":6,"introduction":"中国最具影响力的财经科技信息服务平台之一","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7589,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"自免TCE开始有人掉队了","digest":"文 | 氨基观察 2024年以来,自免领域的TCE彻底火了。 海外大药企持续押注该领域,国产TCE也随之坐上了风口,诞生了国内Biotech出海史上两项价值巨大的交易,包括同润生物和默沙东达成CD3/CD19双抗的收购,合作首付款为7亿美元,仅次于BMS与百利天恒关于双抗ADC的合作; 以及GSK收购恩沐生物的CD3/CD19/CD20三抗CMG1A46的合作,交易首付款为3亿美元,也是较高的水平。 自免TCE的大火是事实,但不可否认,这一领域也充满了未知数。 1月10日,从肿瘤转型自免的IGM Biosciences,就遭遇了打击:核心管线CD20xCD3双抗IGM-2323在自免领域展现的B细胞耗竭深度让人失望。 IGM不得不终止IGM-2323的研发,以及另一款TCE IGM-2644也被迫终止。原因在于,两款TCE的设计思路相同,都采用IgM抗体。但从IGM-2323的表现来看,成功概率可能不大。 失败的消息,让IGM的股价大跌近70%,市值只剩下1.24亿美元。 IGM的遭遇不会是普遍现象。但一定程度上,它如同风向标指明一件事——这个黄金赛道,注定会冰火两重天,火爆的同时,掉队者也会持续出现。 放弃肿瘤,押注自免 过去几年,在自免的热潮下,许多专注于肿瘤研发的biotech,因为各种原因转道自免赛道。IGM也正是这样一家公司。 作为曾经的明星肿瘤biotech,IGM辉煌过,市值曾经超过60亿美金。但随着临床研究的不尽如人意,以及与赛诺菲等重磅合作伙伴的分道扬镳,迫使它做出战略选择。 2023年12月,面对持续减少的现金,IGM开始转向:放弃血液瘤的研发,进入自免领域。 彼时,IGM手中的两款TCE,CD20xCD3双抗IGM-2323、CD38xCD3双抗IGM-2644均在血液瘤领域进行探索,前者针对非霍奇金淋巴瘤,后者针对多发性骨髓瘤。 但IGM决定停止两款","plainDigest":"文 | 氨基观察 2024年以来,自免领域的TCE彻底火了。 海外大药企持续押注该领域,国产TCE也随之坐上了风口,诞生了国内Biotech出海史上两项价值巨大的交易,包括同润生物和默沙东达成CD3/CD19双抗的收购,合作首付款为7亿美元,仅次于BMS与百利天恒关于双抗ADC的合作; 以及GSK收购恩沐生物的CD3/CD19/CD20三抗CMG1A46的合作,交易首付款为3亿美元,也是较高的水平。 自免TCE的大火是事实,但不可否认,这一领域也充满了未知数。 1月10日,从肿瘤转型自免的IGM Biosciences,就遭遇了打击:核心管线CD20xCD3双抗IGM-2323在自免领域展现的B细胞耗竭深度让人失望。 IGM不得不终止IGM-2323的研发,以及另一款TCE IGM-2644也被迫终止。原因在于,两款TCE的设计思路相同,都采用IgM抗体。但从IGM-2323的表现来看,成功概率可能不大。 失败的消息,让IGM的股价大跌近70%,市值只剩下1.24亿美元。 IGM的遭遇不会是普遍现象。但一定程度上,它如同风向标指明一件事——这个黄金赛道,注定会冰火两重天,火爆的同时,掉队者也会持续出现。 放弃肿瘤,押注自免 过去几年,在自免的热潮下,许多专注于肿瘤研发的biotech,因为各种原因转道自免赛道。IGM也正是这样一家公司。 作为曾经的明星肿瘤biotech,IGM辉煌过,市值曾经超过60亿美金。但随着临床研究的不尽如人意,以及与赛诺菲等重磅合作伙伴的分道扬镳,迫使它做出战略选择。 2023年12月,面对持续减少的现金,IGM开始转向:放弃血液瘤的研发,进入自免领域。 彼时,IGM手中的两款TCE,CD20xCD3双抗IGM-2323、CD38xCD3双抗IGM-2644均在血液瘤领域进行探索,前者针对非霍奇金淋巴瘤,后者针对多发性骨髓瘤。 但IGM决定停止两款","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1736750455000,"gmtModify":1736752238676,"symbols":["IE00B66KJ199.SGD","CRS","LU2065731478.USD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","IE0031619046.USD","SLE"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":2572,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/392175303180744","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4599,"displayRows":4,"foldSize":0,"authorId":"3574917796328560"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.365281325269080","cardData":[{"tweetId":"365281325269080","author":{"authorId":"3558920476397107","idStr":"3558920476397107","name":"锦缎","avatar":"https://static.tigerbbs.com/e8eb9e41af832714b14f9e80dd7f2028","userType":6,"introduction":"为上市公司提供知识产权解决方案","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9891,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"小细胞肺癌,长夜渐明","digest":"肺癌是人类“头号杀手”,而在肺癌的诸多类型中,小细胞肺癌(SCLC)又是预后最差的。之所以SCLC预后很差,主要是由两点原因造成的:生长速度快、恶性程度高。SCLC生长速度极快,如果检查不及时,就很容贻误病情;同时SCLC恶性度高,对癌肿周围组织及重要血管极易侵犯。这就导致大多数SCLC患者确诊时都已经处于广泛期(扩散到身体其他部位的侵袭性类型),甚至约 50% 的患者将发生脑转移。SCLC的预后到底有多差呢?患者的5年总生存率仅为 5%~10%,广泛期SCLC(ES-SCLC)患者的中位OS范围仅为12个月左右。虽然SCLC在肺癌总占比并不高,约为15%,但其背后却影响的是全球37.2万名患者的生命。冷冰冰的数字,透露出患者对SCLC新疗法的迫切,现有疗法存在极大的未满足需求。暗夜长空中,透露出一股暖光。在10月24日巴塞罗那举行的2024年EORTC-NCI-AACR(ENA)大会上,再鼎医药以全体会议口头报告的形式,公布了正在进行的ZL-1310全球1a期临床研究数据,在复发的广泛期小细胞肺癌(SCLC)患者中,ZL-1310在所有测试剂量水平的客观缓解率(ORR)达74%。尽管ZL-1310仅处于临床早期,但74%的ORR还是明显超过唯一获批二线靶向疗法Tarlatamab 40%的ORR数据。这是SCLC领域一次新的突破,只要后续ZL-1310进展顺利,那么它极有可能成为SCLC的核心疗法,甚至有望与PD-1联用成为SCLC的一线疗法。一场颠覆,或在悄然发生。01远未满足的SCLC需求依据肿瘤进展情况,SCLC共可分为两大类:局限期SCLC(LS-SCLC)和广泛期SCLC(ES-SCLC)。LS-SCLC,指病变限于一侧胸腔,且能被纳入一个放射治疗野内,对应TNM分期I-III期;ES-SCLC,指病变超过一侧胸腔,且包括恶性胸腔和心包积液或血行转移,对应TNM","plainDigest":"肺癌是人类“头号杀手”,而在肺癌的诸多类型中,小细胞肺癌(SCLC)又是预后最差的。之所以SCLC预后很差,主要是由两点原因造成的:生长速度快、恶性程度高。SCLC生长速度极快,如果检查不及时,就很容贻误病情;同时SCLC恶性度高,对癌肿周围组织及重要血管极易侵犯。这就导致大多数SCLC患者确诊时都已经处于广泛期(扩散到身体其他部位的侵袭性类型),甚至约 50% 的患者将发生脑转移。SCLC的预后到底有多差呢?患者的5年总生存率仅为 5%~10%,广泛期SCLC(ES-SCLC)患者的中位OS范围仅为12个月左右。虽然SCLC在肺癌总占比并不高,约为15%,但其背后却影响的是全球37.2万名患者的生命。冷冰冰的数字,透露出患者对SCLC新疗法的迫切,现有疗法存在极大的未满足需求。暗夜长空中,透露出一股暖光。在10月24日巴塞罗那举行的2024年EORTC-NCI-AACR(ENA)大会上,再鼎医药以全体会议口头报告的形式,公布了正在进行的ZL-1310全球1a期临床研究数据,在复发的广泛期小细胞肺癌(SCLC)患者中,ZL-1310在所有测试剂量水平的客观缓解率(ORR)达74%。尽管ZL-1310仅处于临床早期,但74%的ORR还是明显超过唯一获批二线靶向疗法Tarlatamab 40%的ORR数据。这是SCLC领域一次新的突破,只要后续ZL-1310进展顺利,那么它极有可能成为SCLC的核心疗法,甚至有望与PD-1联用成为SCLC的一线疗法。一场颠覆,或在悄然发生。01远未满足的SCLC需求依据肿瘤进展情况,SCLC共可分为两大类:局限期SCLC(LS-SCLC)和广泛期SCLC(ES-SCLC)。LS-SCLC,指病变限于一侧胸腔,且能被纳入一个放射治疗野内,对应TNM分期I-III期;ES-SCLC,指病变超过一侧胸腔,且包括恶性胸腔和心包积液或血行转移,对应TNM","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1730159280000,"gmtModify":1730206774993,"symbols":["LU0265550946.USD","IE00BLSP4239.USD","LU1291159041.SGD","IE00BJT1NW94.SGD","LU0965509101.SGD","LU1941712264.USD","09688","IE0002141913.USD","IE0031619046.USD","LU0053666078.USD","LU1037948897.HKD","LU0208291251.USD","IE00B19Z4B17.USD","LU1093756168.USD","LU1093756325.SGD","LU1116320737.USD","IE00BFTCPJ56.SGD","LU0265550359.USD","IE00BBT3K403.USD","LU0965509283.SGD","LU1066051811.HKD","LU1917777945.USD","LU1934455863.HKD","LU0203345920.USD","LU1066051225.USD","IE00B66KJ199.SGD","LU1116320901.HKD","LU0203347892.USD","LU0070302665.USD","CRS","LU1057294990.SGD","MRK","LU0106261372.USD","LU1066053197.SGD","L","LU0006306889.USD","LU0234572021.USD","LU1023059063.AUD","LU1430594728.SGD","IE00B1BXHZ80.USD","IE0009355771.USD","LU1934455194.USD","ZLAB"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":3,"images":[{"url":"https://static.tigerbbs.com/189e01b48ff44bbc95d6cd9e44ed74aa"},{"url":"https://static.tigerbbs.com/ea8f383b20434a609095172d137af6f8"},{"url":"https://static.tigerbbs.com/cd6352b2c31b4043ac08d0ed4b7a40c4"}],"repostCount":0,"viewCount":5257,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/365281325269080","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":7156,"displayRows":4,"foldSize":0,"authorId":"3558920476397107"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.330430212599952","cardData":[{"tweetId":"330430212599952","author":{"authorId":"3478213283465426","idStr":"3478213283465426","name":"美股投资网","avatar":"https://static.tigerbbs.com/a1bfd2cf1aa240d7058795c83d419510","userType":6,"introduction":"美股投资网","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":21455,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"特朗普交易:这10只美股蓄势待发","digest":"随着2024年美国总统大选结果的临近,美国政.治.局势的变化正在引发金融市场高度关注。特朗普在竞选遭遇枪击事件,短期内,他可能会获得一些同情分,美国大选经验表明,得摇摆州者得白宫。2024年大选,特朗普在7大摇摆州的民调显著领先。 华尔街分析师开始评估“特朗普交易”可能带来的影响。特朗普的2024年提案和平台呼吁现代化军队、提升国内制造业,并使美国成为全球主导的能源生产国。一些分析师认为,特朗普的税改和放松监管议程开始在市场中体现出来,这会利好金融行业并预计会下发更多并购标准。 <a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$</a> <a href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a> BNP Paribas宏观策略主管Calvin Tse指出:“特朗普交易是一种美国利率曲线陡峭化的策略。特朗普的证策大体上是通胀性的(关税、更宽松的财证证策),与此同时,他可能会任命一位更偏向鸽派的美联储主席。在上周的辩论之后,利率曲线在周五和周一都变得更加陡峭——这可能反映了特朗普获胜的概率上升。” 10 年期减 3 个月国债: 我们关注到有十只“特朗普交易潜力股”,横跨国防、科技、金融等热门板块。这些股票紧密关联特朗普2.0证府可能推行的证策方向,预示着巨大的增长潜力。 01 第一只工业股:Carpenter Technology Corporation(CRS) <a href=\"https://laohu8.com/S/CRS\">$卡朋特科技(CRS)$</a> 是一家领先的高性能特种合金制造商,拥有超过130年的冶金和制造专业知识,专注于生产高性能的特殊金属和合金,包括钛合金和不锈钢。其产品广泛用于航空航天、国防和能源等关键领域。 CRS在截至5月3日的一周内成为最大的工业类股票,涨幅为","plainDigest":"随着2024年美国总统大选结果的临近,美国政.治.局势的变化正在引发金融市场高度关注。特朗普在竞选遭遇枪击事件,短期内,他可能会获得一些同情分,美国大选经验表明,得摇摆州者得白宫。2024年大选,特朗普在7大摇摆州的民调显著领先。 华尔街分析师开始评估“特朗普交易”可能带来的影响。特朗普的2024年提案和平台呼吁现代化军队、提升国内制造业,并使美国成为全球主导的能源生产国。一些分析师认为,特朗普的税改和放松监管议程开始在市场中体现出来,这会利好金融行业并预计会下发更多并购标准。 $英伟达(NVDA)$ $苹果(AAPL)$ BNP Paribas宏观策略主管Calvin Tse指出:“特朗普交易是一种美国利率曲线陡峭化的策略。特朗普的证策大体上是通胀性的(关税、更宽松的财证证策),与此同时,他可能会任命一位更偏向鸽派的美联储主席。在上周的辩论之后,利率曲线在周五和周一都变得更加陡峭——这可能反映了特朗普获胜的概率上升。” 10 年期减 3 个月国债: 我们关注到有十只“特朗普交易潜力股”,横跨国防、科技、金融等热门板块。这些股票紧密关联特朗普2.0证府可能推行的证策方向,预示着巨大的增长潜力。 01 第一只工业股:Carpenter Technology Corporation(CRS) $卡朋特科技(CRS)$ 是一家领先的高性能特种合金制造商,拥有超过130年的冶金和制造专业知识,专注于生产高性能的特殊金属和合金,包括钛合金和不锈钢。其产品广泛用于航空航天、国防和能源等关键领域。 CRS在截至5月3日的一周内成为最大的工业类股票,涨幅为","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1721702084262,"gmtModify":1721731713570,"symbols":["WES","LHX","AGX","DJT","PHUN","RUM","PLTR","CRS","COIN"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":22,"images":[{"url":"https://static.tigerbbs.com/faa070023e8214e700c4a9a313c33076","width":"733","height":"469"},{"url":"https://static.tigerbbs.com/9ac7fc879a337b887472b2911b4fa80b","width":"1080","height":"601"},{"url":"https://static.tigerbbs.com/ded302cc26070c5d83eb0e0699df3807","width":"509","height":"144"}],"repostCount":19,"viewCount":13406,"likeCount":8,"liked":false,"collected":false,"commentCount":6,"hotComments":[{"id":"331061651456080","author":{"authorId":"3488483117770638","idStr":"3488483117770638","name":"快乐金生","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":4,"crmLevelSwitch":1,"fanSize":5,"starInvestorFlag":false},"content":"我20年10月买的这个股票, 现在亏87%","plainContent":"我20年10月买的这个股票, 现在亏87%","likeCount":0,"commentType":"valid","coins":0},{"id":"330442639908904","author":{"authorId":"9000000000000532","idStr":"9000000000000532","name":"抹茶味抹布","avatar":"https://static.tigerbbs.com/b1fa5d9ceb6a8fc80f198e797e2994a9","userType":8,"introduction":"运营账号","crmLevel":1,"crmLevelSwitch":0,"fanSize":14,"starInvestorFlag":false},"content":"特朗普交易的影響潛力很大[丟臉]","plainContent":"特朗普交易的影響潛力很大[丟臉]","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":true,"video":{"poster":"https://static.tigerbbs.com/24f17ae5239844c1c5457d94916aed63","url":"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/f3751cb51253642701646471221/Rde17f0x2EQA.mp4","uuid":"1b417b419ef142259fb5370f0248f84f"},"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/330430212599952","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":9929,"displayRows":4,"foldSize":0,"authorId":"3478213283465426"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.328405442097424","cardData":[{"tweetId":"328405442097424","author":{"authorId":"3527667712494123","idStr":"3527667712494123","name":"格鲁1498","avatar":"https://static.tigerbbs.com/dd05209ce138618bd17e3f60110c2d29","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":34,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"特朗普10家相关概念股,都可以加自选看看:[可爱] <a href=\"https://laohu8.com/S/RUM\">$Rumble Inc.(RUM)$</a> <a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a> <a href=\"https://laohu8.com/S/COIN\">$Coinbase Global, Inc.(COIN)$</a> <a href=\"https://laohu8.com/S/CRS\">$卡朋特科技(CRS)$</a> <a href=\"https://laohu8.com/S/DJT\">$特朗普媒体科技集团(DJT)$</a> <a href=\"https://laohu8.com/S/PHUN\">$Phunware, Inc.(PHUN)$</a> <a href=\"https://laohu8.com/S/AGX\">$Argan Inc.(AGX)$</a> <a href=\"https://laohu8.com/S/LHX\">$哈里斯公司(LHX)$</a> <a href=\"https://laohu8.com/S/WES\">$Western Midstream Operating, LP.(WES)$</a> <a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> 懂王说在大选之前最好不要降息,并说“不会fire鲍威尔”,看来对鲍威尔近期比较鸽派的言论还是满意的,大选前市场看涨[看涨]","plainDigest":"特朗普10家相关概念股,都可以加自选看看:[可爱] $Rumble Inc.(RUM)$ $Palantir Technologies Inc.(PLTR)$ $Coinbase Global, Inc.(COIN)$ $卡朋特科技(CRS)$ $特朗普媒体科技集团(DJT)$ $Phunware, Inc.(PHUN)$ $Argan Inc.(AGX)$ $哈里斯公司(LHX)$ $Western Midstream Operating, LP.(WES)$ $特斯拉(TSLA)$ 懂王说在大选之前最好不要降息,并说“不会fire鲍威尔”,看来对鲍威尔近期比较鸽派的言论还是满意的,大选前市场看涨[看涨]","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1721199977092,"gmtModify":1721200000125,"symbols":["AGX","CRS","TSLA","PHUN","WES","RUM","LHX","PLTR","DJT","COIN"],"themeIds":["fd2c68e6820344cca249bd5c6d5d654b"],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":3833,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/328405442097424","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":true,"upFlag":false,"length":377,"displayRows":4,"foldSize":0,"authorId":"3527667712494123"}],"position":0}],"size":9},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"20760900","market":"us","labels":[],"media":"sec.gov","original_id":"AN196858226000151-CRS","pdf_url":"","pub_time":1771909200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"CRS","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000196858226000151/0001968582-26-000151-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000196858226000151/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEHEoXu2eekFZEybWj","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-24 13:00","pubTimestamp":1771909200,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20751805","market":"us","labels":[],"media":"sec.gov","original_id":"AN195004726001521-CRS","pdf_url":"","pub_time":1771536290000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"CRS","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/0001950047-26-001521-index.html","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000195004726001521/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEEUM6cuRbapYnUSgu","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-20 05:24","pubTimestamp":1771536290,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20750210","market":"us","labels":[],"media":"sec.gov","original_id":"AN196858226000131-CRS","pdf_url":"","pub_time":1771477200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"CRS","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000196858226000131/0001968582-26-000131-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000196858226000131/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEG5DrQURHpgwWAvcS","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-19 13:00","pubTimestamp":1771477200,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20744300","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526054998-CRS","pdf_url":"","pub_time":1771365602000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"CRS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/0001193125-26-054998-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000119312526054998/d109893dex991.htm","primary":true,"translateUrl":"","linkName":"d109893dex991.htm","type":"EX-99.1","id":"NTFILE4sxst7hmU5mtqeDM","market":"us","size":8049},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000119312526054998/d109893d8k.htm","primary":false,"translateUrl":"","linkName":"d109893d8k.htm","type":"8-K","id":"NTFILEFFT9kRD45NU5aYLB","market":"us","size":25772},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000119312526054998/g109893g0217214355973.jpg","primary":false,"translateUrl":"","linkName":"g109893g0217214355973.jpg","type":"GRAPHIC","id":"NTFILEwMYAMR9zirxum6GW","market":"us","size":5592}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-02-18 06:00","pubTimestamp":1771365602,"title_zh":"Form 8-K - Current report","summary_en":"Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第5.02项:董事或某些高级职员的离职;选举董事;若干人员的委任:若干人员的补偿安排;第7.01项:法规FD披露;项目9.01:财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20677163","market":"us","labels":[],"media":"sec.gov","original_id":"AN1784326000009-CRS","pdf_url":"","pub_time":1769662800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"CRS","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000009/0000017843-26-000009-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000009/crs-20251231.htm","primary":true,"translateUrl":"","linkName":"crs-20251231.htm","type":"10-Q","id":"NTFILEBJPbhnf67kjBbrjq","market":"us","size":2051731},{"description":"EX-31.A","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000009/crs-ex31ax20251231.htm","primary":false,"translateUrl":"","linkName":"crs-ex31ax20251231.htm","type":"EX-31.A","id":"NTFILEWoTibgyDkKvgRoTN","market":"us","size":10817},{"description":"EX-31.B","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000009/crs-ex31bx20251231.htm","primary":false,"translateUrl":"","linkName":"crs-ex31bx20251231.htm","type":"EX-31.B","id":"NTFILECsBCpA4bZW31Me3Y","market":"us","size":10835},{"description":"EX-32","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000009/crs-ex32x20251231.htm","primary":false,"translateUrl":"","linkName":"crs-ex32x20251231.htm","type":"EX-32","id":"NTFILEEpSQfioF4i9qUL9F","market":"us","size":7249}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2026-01-29 13:00","pubTimestamp":1769662800,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20676684","market":"us","labels":[],"media":"sec.gov","original_id":"AN1784326000007-CRS","pdf_url":"","pub_time":1769662800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"CRS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000007/0000017843-26-000007-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000007/a2ndqtrfy2026results.htm","primary":true,"translateUrl":"","linkName":"a2ndqtrfy2026results.htm","type":"EX-99.1","id":"NTFILE4MKwKsnG3upAw1MR","market":"us","size":415540},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000007/crs-20260129.htm","primary":false,"translateUrl":"","linkName":"crs-20260129.htm","type":"8-K","id":"NTFILE95FH4gdy1HWgBSAi","market":"us","size":26954}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-01-29 13:00","pubTimestamp":1769662800,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项:经营业绩和财务状况;项目9.01:财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20676594","market":"us","labels":[],"media":"sec.gov","original_id":"AN1784326000005-CRS","pdf_url":"","pub_time":1769662800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"CRS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/0000017843-26-000005-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio.htm","primary":true,"translateUrl":"","linkName":"a2q26earningspresentatio.htm","type":"EX-99.1","id":"NTFILE7vgkTHSNxy9Zwqp9","market":"us","size":27042},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/crs-20260129.htm","primary":false,"translateUrl":"","linkName":"crs-20260129.htm","type":"8-K","id":"NTFILEGLMzB8EempxEaRRT","market":"us","size":26430},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio001.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio001.jpg","type":"GRAPHIC","id":"NTFILE2PyvucZEioT4fNAN","market":"us","size":58962},{"description":"","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio002.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio002.jpg","type":"GRAPHIC","id":"NTFILEAedPpvaDasmTej6c","market":"us","size":188762},{"description":"","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio003.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio003.jpg","type":"GRAPHIC","id":"NTFILEH4xduRFYuZtTmPpb","market":"us","size":36060},{"description":"","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio004.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio004.jpg","type":"GRAPHIC","id":"NTFILEJ9wtAdqQB3YKJEoz","market":"us","size":54054},{"description":"","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio005.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio005.jpg","type":"GRAPHIC","id":"NTFILE3AtL8NUtqLKd8h77","market":"us","size":110591},{"description":"","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio006.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio006.jpg","type":"GRAPHIC","id":"NTFILE6Qc7hggsiVcr1FN3","market":"us","size":107274},{"description":"","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio007.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio007.jpg","type":"GRAPHIC","id":"NTFILEhZuFepZz2BsoxLTv","market":"us","size":41629},{"description":"","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio008.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio008.jpg","type":"GRAPHIC","id":"NTFILEDLWyPgBswLDaiyS3","market":"us","size":102750},{"description":"","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio009.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio009.jpg","type":"GRAPHIC","id":"NTFILEGScvQqW4XYNHtCAp","market":"us","size":122927},{"description":"","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio010.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio010.jpg","type":"GRAPHIC","id":"NTFILEEUSK1DUB8cA5hbQH","market":"us","size":127574},{"description":"","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio011.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio011.jpg","type":"GRAPHIC","id":"NTFILE9h5FgTF6queNHmAm","market":"us","size":142738},{"description":"","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio012.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio012.jpg","type":"GRAPHIC","id":"NTFILE7hVKiJU1UPot2hYQ","market":"us","size":42081},{"description":"","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio013.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio013.jpg","type":"GRAPHIC","id":"NTFILE2uRpHMdbHXfCGUgu","market":"us","size":131188},{"description":"","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio014.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio014.jpg","type":"GRAPHIC","id":"NTFILE8QbvsUDYag3PpvVf","market":"us","size":130434},{"description":"","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio015.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio015.jpg","type":"GRAPHIC","id":"NTFILEG8APVHmkHNs4Wt99","market":"us","size":30701},{"description":"","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio016.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio016.jpg","type":"GRAPHIC","id":"NTFILE2DtRvSY3PRDzMedi","market":"us","size":88705},{"description":"","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio017.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio017.jpg","type":"GRAPHIC","id":"NTFILE2e1H4ZQ8YHj85jq9","market":"us","size":100964},{"description":"","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio018.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio018.jpg","type":"GRAPHIC","id":"NTFILEDwRyHYVWJta8wWih","market":"us","size":84477},{"description":"","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio019.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio019.jpg","type":"GRAPHIC","id":"NTFILE5Dtsax7odVnwjfrU","market":"us","size":69687},{"description":"","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000001784326000005/a2q26earningspresentatio020.jpg","primary":false,"translateUrl":"","linkName":"a2q26earningspresentatio020.jpg","type":"GRAPHIC","id":"NTFILE8hMxj6j3gapqvifb","market":"us","size":74193}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-01-29 13:00","pubTimestamp":1769662800,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项:经营业绩和财务状况;项目9.01:财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20519914","market":"us","labels":[],"media":"sec.gov","original_id":"AN195004725010128-CRS","pdf_url":"","pub_time":1765429200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"CRS","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000195004725010128/0001950047-25-010128-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000195004725010128/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE2MzoX7hjfLgAEdjX","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-12-11 13:00","pubTimestamp":1765429200,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20515747","market":"us","labels":[],"media":"sec.gov","original_id":"AN195004725010115-CRS","pdf_url":"","pub_time":1765342800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"CRS","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000195004725010115/0001950047-25-010115-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000195004725010115/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEGTxWAvGTyfHS7aw5","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-12-10 13:00","pubTimestamp":1765342800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20509625","market":"us","labels":[],"media":"sec.gov","original_id":"AN195004725010025-CRS","pdf_url":"","pub_time":1765256400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"CRS","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000195004725010025/0001950047-25-010025-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000195004725010025/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE24DviGooMiYydiYr","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-12-09 13:00","pubTimestamp":1765256400,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20456006","market":"us","labels":[],"media":"sec.gov","original_id":"AN195004725009447-CRS","pdf_url":"","pub_time":1764133200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"CRS","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000195004725009447/0001950047-25-009447-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000195004725009447/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE6wnSrV6VaNg6YvE6","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-11-26 13:00","pubTimestamp":1764133200,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20439688","market":"us","labels":[],"media":"sec.gov","original_id":"AN162828025053610-CRS","pdf_url":"","pub_time":1763701200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"CRS","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000162828025053610/0001628280-25-053610-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000162828025053610/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE8Zp4XzTRdnf3i3Uj","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-11-21 13:00","pubTimestamp":1763701200,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20434778","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925114628-CRS","pdf_url":"","pub_time":1763614800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"CRS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000110465925114628/0001104659-25-114628-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 4.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925114628/tm2531768d1_ex4-1.htm","primary":true,"translateUrl":"","linkName":"tm2531768d1_ex4-1.htm","type":"EX-4.1","id":"NTFILEnsBvEHxe99zGq8sa","market":"us","size":575438},{"description":"FORM 8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925114628/tm2531768d1_8k.htm","primary":false,"translateUrl":"","linkName":"tm2531768d1_8k.htm","type":"8-K","id":"NTFILE8HX7kS8CgTWdKagj","market":"us","size":33771},{"description":"EXHIBIT 10.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925114628/tm2531768d1_ex10-1.htm","primary":false,"translateUrl":"","linkName":"tm2531768d1_ex10-1.htm","type":"EX-10.1","id":"NTFILEBAvJEFMpXDWWY4Nb","market":"us","size":1029883},{"description":"EXHIBIT 99.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925114628/tm2531768d1_ex99-1.htm","primary":false,"translateUrl":"","linkName":"tm2531768d1_ex99-1.htm","type":"EX-99.1","id":"NTFILE4Sgf45qbjuXT42Lm","market":"us","size":11361},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925114628/tm2531768d1_ex99-1img001.jpg","primary":false,"translateUrl":"","linkName":"tm2531768d1_ex99-1img001.jpg","type":"GRAPHIC","id":"NTFILEt8xnw6QugtkAbLYX","market":"us","size":23783}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-11-20 13:00","pubTimestamp":1763614800,"title_zh":"Form 8-K - Current report","summary_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第1.01项:签订重大最终协议;第2.03项:直接财务义务或注册人资产负债表外安排下的义务的产生;第7.01项:法规FD披露;项目9.01:财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20391576","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925109178-CRS","pdf_url":"","pub_time":1762810203000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"CRS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/0001104659-25-109178-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925109178/tm2530700d1_ex99-1.htm","primary":true,"translateUrl":"","linkName":"tm2530700d1_ex99-1.htm","type":"EX-99.1","id":"NTFILE5R9EhLitx3YAPxSg","market":"us","size":10701},{"description":"FORM 8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925109178/tm2530700d1_8k.htm","primary":false,"translateUrl":"","linkName":"tm2530700d1_8k.htm","type":"8-K","id":"NTFILEBqETuurLULTr49yB","market":"us","size":26426},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925109178/tm2530700d1_ex99-1img01.jpg","primary":false,"translateUrl":"","linkName":"tm2530700d1_ex99-1img01.jpg","type":"GRAPHIC","id":"NTFILEBNwuRxvMnMLZHfdo","market":"us","size":7021}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-11-11 05:30","pubTimestamp":1762810203,"title_zh":"Form 8-K - Current report","summary_en":"Item 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第7.01项:法规FD披露;项目9.01:财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20389018","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925108831-CRS","pdf_url":"","pub_time":1762750800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"CRS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/17843/000110465925108831/0001104659-25-108831-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925108831/tm2530700d2_ex99-1.htm","primary":true,"translateUrl":"","linkName":"tm2530700d2_ex99-1.htm","type":"EX-99.1","id":"NTFILEJ8rLCAp5RCsJcbyf","market":"us","size":10243},{"description":"FORM 8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925108831/tm2530700d2_8k.htm","primary":false,"translateUrl":"","linkName":"tm2530700d2_8k.htm","type":"8-K","id":"NTFILE8bjqSnNbeHHssaGL","market":"us","size":33038},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/17843/000110465925108831/tm2530700d2_ex99-1img001.jpg","primary":false,"translateUrl":"","linkName":"tm2530700d2_ex99-1img001.jpg","type":"GRAPHIC","id":"NTFILEB64F6sy9frC9DvEH","market":"us","size":11725}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-11-10 13:00","pubTimestamp":1762750800,"title_zh":"Form 8-K - Current report","summary_en":"Item 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第7.01项:法规FD披露;项目9.01:财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.carpentertechnology.com","stockEarnings":[{"period":"1week","weight":-0.0003},{"period":"1month","weight":-0.0239},{"period":"3month","weight":0.1571},{"period":"6month","weight":0.5817},{"period":"1year","weight":1.0897},{"period":"ytd","weight":0.2435}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Carpenter Technology Corporation成立于1889年,是特拉华州的一家公司。该公司从事特种金属的制造和分销。该公司是优质特种合金的生产商和分销商,包括钛合金、粉末金属、不锈钢、合金钢和工具钢。在航空航天、国防、医疗、运输、能源、工业和消费市场的关键应用领域,该公司是公认的高性能特种合金材料和工艺解决方案的领导者。该公司已经发展成为优质特种合金的先驱,包括钛、镍和钴,以及专门为增材制造工艺和软磁应用设计的合金。","yearOnYearQuotes":[{"month":1,"riseRate":0.456522,"avgChangeRate":-0.006705},{"month":2,"riseRate":0.652174,"avgChangeRate":0.027439},{"month":3,"riseRate":0.521739,"avgChangeRate":0.000589},{"month":4,"riseRate":0.553191,"avgChangeRate":0.043832},{"month":5,"riseRate":0.543478,"avgChangeRate":0.024379},{"month":6,"riseRate":0.521739,"avgChangeRate":-0.000496},{"month":7,"riseRate":0.5,"avgChangeRate":0.022964},{"month":8,"riseRate":0.456522,"avgChangeRate":-0.007895},{"month":9,"riseRate":0.608696,"avgChangeRate":-0.003285},{"month":10,"riseRate":0.347826,"avgChangeRate":-0.015075},{"month":11,"riseRate":0.717391,"avgChangeRate":0.060126},{"month":12,"riseRate":0.608696,"avgChangeRate":0.016172}],"exchange":"NYSE","name":"卡朋特科技","nameEN":"Carpenter Technology"},"aProfile":null}}}